Vertex Pharmaceuticals (VRTX) Q3 2024 earnings summary

Executive summary

• Q3 2024 product revenue grew 12% year-over-year to $2.77–$2.8 billion, driven by strong CF franchise, TRIKAFTA/KAFTRIO demand, and initial Casgevy sales.

• Full-year 2024 product revenue guidance raised to $10.8–$10.9 billion, reflecting robust commercial execution, pipeline progress, and new launches.

• Preparing for major product launches in early 2025: vanzacaftor triple for CF and suzetrigine for acute pain, both with FDA priority review.

• Alpine Immune Sciences acquisition expensed as $4.4 billion AIPR&D in 2024, impacting net income and cash position.

• Multiple late-stage pipeline programs advancing, with five launches targeted over five years.

Financial highlights

• Q3 2024 revenue grew 12% year-over-year to $2.77–$2.8 billion; U.S. up 10%, ex-U.S. up 14%.

• Q3 non-GAAP operating income was $1.31 billion, up from $1.17 billion in Q3 2023; non-GAAP operating margin 47%.

• GAAP net income for Q3 2024 was $1.05 billion; non-GAAP net income $1.14 billion ($4.38 per diluted share).

• Cash, cash equivalents, and marketable securities totaled $11.2 billion at quarter-end, down from $13.7 billion due to Alpine acquisition and share repurchases.

• Q3 non-GAAP R&D and SG&A expenses rose year-over-year, reflecting commercial and pipeline investments.

Outlook and guidance

• Full-year 2024 product revenue guidance raised to $10.8–$10.9 billion, representing 10% growth at midpoint.

• Non-GAAP R&D and SG&A expenses expected at $4.2–$4.3 billion for 2024.

• 2024 AIPR&D expenses expected at ~$4.6 billion, including $4.4 billion from Alpine acquisition.

• Non-GAAP effective tax rate for 2024 expected at ~19.8%, impacted by non-deductible Alpine AIPR&D expense.

• Preparing for potential launches of vanzacaftor triple (CF) and suzetrigine (acute pain) in early 2025.